Company news

Moderna, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates

February 21, 2024

Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering

February 6, 2024

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

January 31, 2024

Moderna Named to Fortune's List of World's Most Admired Companies

January 30, 2024

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine

December 13, 2023

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following...

December 13, 2023

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025

December 11, 2023

Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

December 10, 2023

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event

December 6, 2023

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023

November 13, 2023

Moderna to Present at Upcoming Conferences in November 2023

November 7, 2023

Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event

November 7, 2023

Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year

November 6, 2023

Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates

November 1, 2023

CEPI y Moderna aprovechan la tecnología ARNm para avanzar en la Misión de los 100 días

October 29, 2023

Moderna Named a Top Employer by Science for Ninth Consecutive Year

October 25, 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19

October 23, 2023

Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

October 23, 2023

Moderna to Host Second Digital Investor Event on November 8th, 2023

October 18, 2023

Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023

October 11, 2023

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19

October 3, 2023

Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation

September 28, 2023

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union

September 13, 2023

Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease

September 12, 2023

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine

September 10, 2023

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

September 10, 2023

Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

September 7, 2023

Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference

September 5, 2023

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86

September 5, 2023

Moderna to Host Investor Event - R&D Day and Business Updates

August 29, 2023

Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

August 16, 2023

Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 2, 2023

Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

July 25, 2023

Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

July 12, 2023

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345

July 4, 2023

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

July 2, 2023

Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine

June 21, 2023

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Mela...

June 4, 2023

Moderna to Present at Upcoming Conferences in June 2023

May 31, 2023

Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting

May 29, 2023

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting

May 18, 2023

Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates

May 3, 2023

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting

May 2, 2023

Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines

May 1, 2023

Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

April 19, 2023

Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science

April 19, 2023

Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Followi...

April 15, 2023

Moderna Announces Clinical and Program Updates at 4th Vaccines Day

April 10, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 63 decks. Every deck is listed under its year.